Latest News

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
02/03/16AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in February
REDWOOD CITY, Calif., Feb. 3, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Financial Officer and Head of Business Development, Timothy E. Morris will be presenting at the 18th Annual BIO CEO & Investor Conference and the 2016 RBC Capital Markets' Healthcare Conference in New York. Details of the conference... 
Printer Friendly Version
01/21/16AcelRx Pharmaceuticals Announces Presentation of Phase 3 Sufentanil Sublingual 30 mcg Tablet (ARX-04) Data at the European Congress of Ambulatory Surgery
Phase 3 Clinical Data Highlights Safety and Efficacy of Sublingual Sufentanil in Outpatient Abdominal Surgery Populations REDWOOD CITY, Calif., Jan. 21, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a presentation will be made at the annual European Congress of Ambulatory Surgery to be held January 28th and 29th, 2016 at the Disneyland Hotel New York Convention Centre in Paris, France.  This bilingual congress (simultaneous translation will be provided)... 
Printer Friendly Version
01/10/16AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones
- ARX-04 ER and Postoperative Study Results, NDA Submission - Initiation and Completion of Final Phase 3 trial in the U.S. for Zalviso, NDA Resubmission - Zalviso™ Commercial Launch in the European Union REDWOOD CITY, Calif., Jan. 10, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced anticipated 2016 milestones for i... 
Printer Friendly Version
01/08/16AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312) for Zalviso™ in 1Q 2016
REDWOOD CITY, Calif., Jan. 8, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported that the Company has received comments from the Division of Anesthesia, Analgesia, and Addiction Products (Division) of the U.S. Food and Drug Administration (FDA) on the Company's proposed protocol for a Phase 3 clinical study (IAP312) d... 
Printer Friendly Version

AcelRX

CONTACT